CA3180351A1 - Leriglitazone for treating lung inflammation and interstitial lung disease - Google Patents

Leriglitazone for treating lung inflammation and interstitial lung disease

Info

Publication number
CA3180351A1
CA3180351A1 CA3180351A CA3180351A CA3180351A1 CA 3180351 A1 CA3180351 A1 CA 3180351A1 CA 3180351 A CA3180351 A CA 3180351A CA 3180351 A CA3180351 A CA 3180351A CA 3180351 A1 CA3180351 A1 CA 3180351A1
Authority
CA
Canada
Prior art keywords
phenyl
ethoxy
subject
lung
dione
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3180351A
Other languages
English (en)
French (fr)
Inventor
Marc Martinell Pedemonte
Maria Pilar Pizcueta Lalanza
Anna VILALTA SAURA
Estefania TRAVER LOPEZ
Sonia MARIA POLI
Nuria IZQUIERDO USEROS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Minoryx Therapeutics SL
Original Assignee
Minoryx Therapeutics SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minoryx Therapeutics SL filed Critical Minoryx Therapeutics SL
Publication of CA3180351A1 publication Critical patent/CA3180351A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA3180351A 2020-04-30 2021-04-30 Leriglitazone for treating lung inflammation and interstitial lung disease Pending CA3180351A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20382356 2020-04-30
EP20382356.2 2020-04-30
PCT/IB2021/053651 WO2021220250A1 (en) 2020-04-30 2021-04-30 Leriglitazone for treating lung inflammation and interstitial lung disease

Publications (1)

Publication Number Publication Date
CA3180351A1 true CA3180351A1 (en) 2021-11-04

Family

ID=70779625

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3180351A Pending CA3180351A1 (en) 2020-04-30 2021-04-30 Leriglitazone for treating lung inflammation and interstitial lung disease

Country Status (11)

Country Link
US (1) US20230172921A1 (https=)
EP (1) EP4142720A1 (https=)
JP (1) JP2023525981A (https=)
KR (1) KR20230035522A (https=)
CN (1) CN116390725A (https=)
AU (1) AU2021265345A1 (https=)
BR (1) BR112022021951A2 (https=)
CA (1) CA3180351A1 (https=)
IL (1) IL297771A (https=)
MX (1) MX2022013021A (https=)
WO (1) WO2021220250A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4642456A1 (en) * 2022-12-28 2025-11-05 Minoryx Therapeutics S.L. Optimized dosing of leriglitazone
WO2024231881A2 (en) * 2023-05-09 2024-11-14 Minoryx Therapeutics S.L. Polymorphic forms and formulations of leriglitazone

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ590774A (en) * 2008-08-07 2012-09-28 Pulmagen Therapeutics Inflammation Ltd Substantially pure 5R enantiomers of pioglitazone and rosiglitazone for treating inflammatory respiratory diseases
WO2010150014A1 (en) * 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
WO2011047048A1 (en) * 2009-10-14 2011-04-21 Gemmus Pharma, Inc. Combination therapy treatment for viral infections
WO2011073662A1 (en) * 2009-12-17 2011-06-23 Astrazeneca Ab Combination of a benzoxazinone and a further agent for treating respiratory diseases
EA202091120A3 (ru) 2014-04-02 2020-12-30 Минорикс Терапьютикс С.Л. Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы
JP7040798B2 (ja) * 2016-12-01 2022-03-23 ミノリックス セラピューティクス エセ．エレ． 非アルコール性脂肪性肝疾患を処置するための５－［［４－［２－［５－（１－ヒドロキシエチル）ピリジン－２－イル］エトキシ］フェニル］メチル］－１，３－チアゾリジン－２，４－ジオン
CN112823004A (zh) * 2018-06-06 2021-05-18 米尼奥尔克斯治疗有限公司 5-[[4-[2-[5-乙酰基吡啶-2-基]乙氧基]苄基]-1,3-噻唑烷-2,4-二酮及其盐的用途

Also Published As

Publication number Publication date
WO2021220250A1 (en) 2021-11-04
MX2022013021A (es) 2023-01-16
IL297771A (en) 2022-12-01
CN116390725A (zh) 2023-07-04
JP2023525981A (ja) 2023-06-20
AU2021265345A1 (en) 2022-12-08
KR20230035522A (ko) 2023-03-14
EP4142720A1 (en) 2023-03-08
US20230172921A1 (en) 2023-06-08
BR112022021951A2 (pt) 2022-12-13

Similar Documents

Publication Publication Date Title
Magro COVID-19: Review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking
US20230241014A1 (en) Mek-inhibitors for the treatment or prevention of coronavirus infections and/or covid-19 cytokine storm
US20110295365A1 (en) Anti-viral compositions and methods for administration
US12551469B2 (en) Sphingosine kinase 2 inhibitor for treating coronavirus infection
US20230218596A1 (en) Methods involving neutrophil elastase inhibitor alvelestat for treating coronavirus infection
EP4103207A1 (en) Prevention and treatment of infections including those caused by coronavirus
US20240082202A1 (en) Compositions And Methods for Treating Acute Respiratory Distress Syndrome (ARDS) And Inflammatory Disorders Caused by Corona Viruses and Other Respiratory Pathogens or Agents That Mediate Pulmonary Injury, Inflammation or Acute Respiratory Distress, And Related Compositions and Methods for Treating and Preventing Human SARS Coronavirus Infection, COVID-19 Disease and Related Symptoms
KR20240073720A (ko) Covid-19 질환을 치료하는 신규 조성물 및 방법
Mahajan et al. Plcγ2/Tmem178 dependent pathway in myeloid cells modulates the pathogenesis of cytokine storm syndrome
US20230172921A1 (en) Leriglitazone for treating lung inflammation and interstitial lung disease
JP2023517220A (ja) 微生物感染症の治療のためのｎｋ細胞およびそれらの使用
KR20220166809A (ko) 급성 호흡곤란 증후군 및 바이러스 감염 치료를 위한 cxcr4 억제제
Johnson et al. Robust innate immune responses at the placenta during early gestation may limit in utero HIV transmission
Tutak et al. A patient presenting with ARDS after COVID-19 vaccination: a COVID-19 case report
US20180169108A1 (en) Drug Combinations For the Treatment of HIV
HK40096631A (zh) 用於治疗肺部炎症和间质性肺病的羟基吡格列酮
EP4115885A1 (en) A pharmaceutical composition comprising bay 86-5277 and salts thereof for use in the treatment of viral infections and hyperinflammation
US20230226095A1 (en) Methods and compositions for treating coronavirus infectious disease
TW202245799A (zh) 治療冠狀病毒感染及由其導致之發炎所誘發的肺損傷之方法
US11471448B2 (en) Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia
RU2837859C1 (ru) Лечение коронавирусной инфекции
Haw et al. TLR7 promotes smoke-induced lung damage through the activity of mast cell tryptase
Ravindra Babu et al. Possible Mechanisms of Drugs Used in the Treatment of COVID-19: A Pharmacological Perspective
Ramezaninejad et al. The Efficacy and Safety of Adding Chlorpromazine to Atazanavir/Ritonavir Regimen in the Treatment of Moderate COVID-19 Patients, a Randomized Double-blind Clinical Trial
Chen Systemic and Local Innate Immune Dysfunction Drives Acute COVID-19 and Post COVID Syndrome

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251015

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251215

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260204